Codice QR

Prospective REALITI-A StudyTake-home Points

Background: Mepolizumab, a monoclonal antibody targeting IL-5, is of proven clinical benefit in severe asthma; however, prospective, long-term, real-world data in severe asthma are required. Research Question: What is the real-world benefit of 2 years of mepolizumab treatment in severe asthma? Study...

Descrizione completa

Salvato in:
Autori principali: Cristiano Caruso, MD, PhD, G. Walter Canonica, MD, Manish Patel, MBChB, PhD, Andrew Smith, MBChB, PhD, Mark C. Liu, MD, Rafael Alfonso-Cristancho, MD, PhD, Robert G. Price, MSc, Rupert W. Jakes, PhD, Lydia Demetriou, MSc, Antonio Valero, MD, Thomas C. Köhler, MD, Charles Pilette, MD, PhD, Geoffrey Chupp, MD, Guy Brusselle, MD, Peter Howarth, DM
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2025-03-01
Serie:CHEST Pulmonary
Soggetti:
asthma exacerbations
long-term
mepolizumab
oral corticosteroids
real world
severe asthma
Accesso online:http://www.sciencedirect.com/science/article/pii/S2949789224000734
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi